Hundreds of Overseas Flights Canceled After Mask Rules Dropped
THURSDAY, April 7, 2022 (HealthDay News) — Just weeks after dropping masking rules, some overseas airlines have canceled hundreds of flights as they struggle with staffing shortages related to COVID-19. This comes as the leading U.S. airlines have ur…
Learn MoreDespite Improvements, Disparities in Faculty Diversity Persist
THURSDAY, April 7, 2022 (HealthDay News) — From 1977 to 2019, there was an increase in the representation of women compared with men at U.S. medical faculties, while representation of persons underrepresented in medicine (URM) increased about twofold…
Learn MoreMiddle Ear Effusion Up for Children With Tracheostomy on Ventilator
THURSDAY, April 7, 2022 (HealthDay News) — For children with a tracheostomy, the likelihood of developing middle ear effusion (MEE) is increased for those requiring mechanical ventilation, according to a study published in the April issue of the Inte…
Learn MoreACC: Low-Sodium Intervention Has Little Benefit in Heart Failure
THURSDAY, April 7, 2022 (HealthDay News) — A dietary intervention to reduce sodium intake is feasible for patients with chronic heart failure but does not improve clinical outcomes, according to a study published online April 2 in The Lancet to coincide with the annual meeting of the American College of Cardiology, held from April 2 to 4 in Washington, D.C.
Justin A. Ezekowitz, M.B.B.Ch., from the University of Alberta in Edmonton, Canada, and colleagues conducted an open-label, randomized controlled trial enrolling 806 patients with chronic heart failure receiving optimally tolerated guideline-directed medical treatment at 26 sites in six countries. Participants were randomly assigned to usual care or a low-sodium diet of less than 100 mmol (
The researchers found that median sodium intake decreased from 2,286 to 1,658 mg/day from baseline to 12 months in the low-sodium group and from 2,119 to 2,073 mg/day in the usual care group. By 12 months, the primary outcome (composite of cardiovascular-related admission to hospital, cardiovascular-related emergency department visit, or all-cause death) occurred in 15 and 17 percent of patients in the low-sodium and usual care groups, respectively (hazard ratio, 0.89; 95 percent confidence interval, 0.63 to 1.26; P = 0.53). No significant differences were seen between the groups in terms of all-cause death, cardiovascular-related hospitalization, and cardiovascular-related emergency department visits. Neither group reported safety events related to the study treatment.
“The dietary intervention in this study was feasible and effective in reducing sodium intake in patients with heart failure but did not result in changes in clinical outcomes,” the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Learn MoreSitting Tai Chi Program Benefits Subacute Stroke Survivors
THURSDAY, April 7, 2022 (HealthDay News) — A tailored 12-week sitting tai chi program is beneficial for the recovery of subacute stroke survivors, according to a study published online April 7 in Stroke.Jie Zhao, Ph.D., from the Yunnan University of …
Learn MoreTebipenem Pivoxil Hydrobromide Noninferior to Ertapenem for UTI
THURSDAY, April 7, 2022 (HealthDay News) — For patients with complicated urinary tract infection or acute pyelonephritis, tebipenem pivoxil hydrobromide is noninferior to intravenous ertapenem, according to a study published in the April 7 issue of t…
Learn MoreFear of Cancer Recurrence Prevalent in Patients, Survivors
THURSDAY, April 7, 2022 (HealthDay News) — Fear of cancer recurrence (FCR) affects a considerable number of cancer survivors and patients, across cancer types and continents, according to a review published online April 7 in Psycho-Oncology.Yvonne Lu…
Learn MoreACC: Bleeding Risk Lower With Tranexamic Acid in Noncardiac Surgery
THURSDAY, April 7, 2022 (HealthDay News) — For patients undergoing noncardiac surgery, the incidence of a composite bleeding outcome is significantly lower with tranexamic acid, while tranexamic acid is not noninferior for the composite cardiovascular outcome, according to a study published online April 2 in the New England Journal of Medicine to coincide with the annual meeting of the American College of Cardiology, held from April 2 to 4 in Washington, D.C.
P.J. Devereaux, M.D., Ph.D., from McMaster University in Hamilton, Ontario, Canada, and colleagues conducted a trial involving 9,535 patients undergoing noncardiac surgery who were randomly assigned to receive either tranexamic acid or placebo (4,757 and 4,778 patients, respectively).
The researchers found that a composite bleeding outcome (life-threatening bleeding, major bleeding, or bleeding into a critical organ) at 30 days occurred in 9.1 and 11.7 percent of patients in the tranexamic acid and placebo groups, respectively (hazard ratio, 0.76; 95 percent confidence interval, 0.67 to 0.87; two-sided P
“Although the difference in composite cardiovascular complications between the tranexamic acid group and the placebo group was small, the noninferiority of tranexamic acid was not established,” the authors write.
Several authors disclosed financial ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Learn MoreSubstance Use Treatment Cuts Depression With Co-Occurrence
THURSDAY, April 7, 2022 (HealthDay News) — Among teens with substance use and depression, roughly one-third show early improvements in depression during treatment for substance use, according to a study published in the April issue of the Journal of …
Learn MoreEligibility Criteria Add to Race Gap in Pancreatic Cancer Clinical Trials
THURSDAY, April 7, 2022 (HealthDay News) — Traditional eligibility criteria differentially exclude Black patients from participating in clinical trials for pancreatic ductal adenocarcinoma (PDAC), according to a study published online March 22 in the…
Learn More